Abstract
Background A pilot programme of Cohort Event Monitoring (CEM) was conducted across the six geopolitical zones of Nigeria on patients treated for uncomplicated malaria with artemisinin-based combination therapy (ACT). The emergence and spread of malaria parasites resistant to commonly available antimalarial drugs necessitated a shift in policy for malaria treatment by the Federal Government from the use of chloroquine and sulphadoxine-pyrimethamine (SP) as first-line treatments to ACTs. Initial reports following deployment of ACTs in clinical settings raised safety concerns regarding their use. Although artemisinin and its derivatives are generally thought to be safe, there are currently few or no data on their safety among populations in Nigeria. Objectives The main objectives of the CEM programme were to proactively determine the adverse event (AE) profile of artesunate/amodiaquine (AA) and artemether/ lumefantrine (AL) in real-life settings and to find out the factors predisposing to AEs. Methods The CEM study was observational, longitudinal, prospective, and inceptional. Patients were observed in real-life situations. It was conducted in six public health facilities in Nigeria on patients with a clinical diagnosis of uncomplicated malaria treated with ACTs. Patients were prescribed one of the ACTs on an alternate basis as they enrolled into the programme. Follow-up reviews were undertaken on days 3 and 7 following commencement of ACT treatment. At follow-up, patients were evaluated for any clinical event that they might have experienced
Bassi, P (2021). Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study. Afribary. Retrieved from https://track.afribary.com/works/safety-of-artemisinin-based-combination-therapies-in-nigeria-a-cohort-event-monitoring-study
Bassi, Peter "Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study" Afribary. Afribary, 16 May. 2021, https://track.afribary.com/works/safety-of-artemisinin-based-combination-therapies-in-nigeria-a-cohort-event-monitoring-study. Accessed 23 Nov. 2024.
Bassi, Peter . "Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study". Afribary, Afribary, 16 May. 2021. Web. 23 Nov. 2024. < https://track.afribary.com/works/safety-of-artemisinin-based-combination-therapies-in-nigeria-a-cohort-event-monitoring-study >.
Bassi, Peter . "Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study" Afribary (2021). Accessed November 23, 2024. https://track.afribary.com/works/safety-of-artemisinin-based-combination-therapies-in-nigeria-a-cohort-event-monitoring-study